Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05031455
Other study ID # SHUCSD06242020
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 25, 2024
Est. completion date February 28, 2026

Study information

Verified date April 2024
Source Scripps Clinic
Contact Andrew White, MD
Phone 858-764-9010
Email white.andrew@scrippshealth.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Aspirin-Exacerbated Respiratory Disease (AERD), although uncommon in the general population, is an important phenotype of severe asthma and nasal polyposis where it occurs in 15% of severe asthmatics, and up to 30% of those with nasal polyposis. An important therapy for AERD is aspirin therapy after desensitization (ADAT). This is an inexpensive and proven therapy to improve the burden of sinus disease in AERD. Aspirin desensitization is the mechanism by which tolerance is induced in AERD patients. This is a 1-2 day outpatient procedure whereby increasing doses of aspirin are administered and the patients invariably experience some degree of hypersensitivity reactions. It is important to understand the effect of medications on the aspirin desensitization. It is known that the leukotriene modifier medications decrease the severity of the reactions in AERD. Other treatments such as antihistamines and the biologic agent omalizumab might have an effect on either blocking or blunting reactivity in AERD during desensitization. Dupilumab is a new respiratory biologic approved for atopic dermatitis, eosinophilic asthma and nasal polyposis. As such, it is well situated to be used for many AERD patients whose disease cannot be well controlled. The effect of dupilumab on the aspirin desensitization process and reaction is unknown and is the topic of this investigation. The primary objective is to determine the effect of dupilumab on reactions during aspirin challenge/desensitization.


Recruitment information / eligibility

Status Recruiting
Enrollment 16
Est. completion date February 28, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects >18 years old with Aspirin-Exacerbated Respiratory Disease This is diagnosed via either a positive oral aspirin or intranasal ketorolac challenge OR a history of at least two stereotypical hypersensitivity reactions to aspirin leading to nasal-ocular symptom and/or asthmatic symptoms. - Current treatment with dupilumab at standard asthma/nasal polyposis dosing of 300mg subcutaneously every 2 weeks for a minimum of 12 weeks. - All subjects will be required to have a known history of nasal polyposis either via imaging, endoscopy, or nasal examination Exclusion Criteria: - History of gastrointestinal reactions (severe abdominal pain with or without vomiting) during NSAID triggered events - Unstable asthma or history of severe reactions during previous desensitization attempts - inability to take montelukast pretreatment - history of gastrointestinal bleeding or bleeding disorder - pregnancy - previous use of any other respiratory biologic in the past 3 months (omalizumab, tezepelumab, mepolizumab, reslizumab, benralizumab) - need for systemic corticosteroids to stabilize asthma prior to challenge - time from sinus surgery <1 month.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Aspirin Challenge
Dupilumab is a fully human monoclonal antibody that blocks the receptor component for IL-4 and IL-13, which are key drivers of type 2 inflammation. All subjects will be prescribed this at standard 300mg subcutaneous dosing every 2 weeks. The intervention will be the response to aspirin challenge. All 16 subjects will receive dupilumab. All subjects will undergo an aspirin challenge/desensitization procedure. It is estimated that 50% of subjects will have a respiratory reaction to aspirin and 50% will not. There will not be any randomization.

Locations

Country Name City State
United States Scripps Clini San Diego California

Sponsors (3)

Lead Sponsor Collaborator
Scripps Clinic Regeneron Pharmaceuticals, University of California, San Diego

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of positive challenges to aspirin challenge Aspirin challenge reactions will be defined as either 1) >15% drop in FEV1 or 2) >25% drop in peak nasal inspiratory flow (PNIF) or 3) >5 point change in composite symptom score.
Spirometry is a standardized measure of airflow obstruction used to define lower airway reaction to aspirin in AERD.
Nasal inspiratory flow rates are measured using an inverted peak flow meter and have been correlated with nasal obstruction occurring during nasal reactions to aspirin in AERD.
Symptom Score - symptoms are a typical part of an aspirin reaction with increase in congestion, itching, cough, and chest tightness.
Aspirin challenge = 6 weeks after starting dupilumab/placebo. Aspirin challenge day = up to 8 hours
See also
  Status Clinical Trial Phase
Completed NCT03595488 - Dupilumab for Aspirin-exacerbated Respiratory Disease Phase 2
Enrolling by invitation NCT03627481 - Sleep Quality After Nasosinusal Surgery in AERD Patients N/A
Recruiting NCT05672030 - Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP
Completed NCT03849625 - Characteristics of Patients Diagnosed With NSAID Sensitivity in Thailand
Active, not recruiting NCT03973749 - Effects of a High or Low Salycilate Diet on Urinary LTE4 and Clinical Features in AERD N/A
Recruiting NCT04147013 - Effect of Celecoxib on Postoperative Analgesia and Disease Severity in AERD Patients With CRS Phase 4
Completed NCT01631773 - A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only N/A
Recruiting NCT05575037 - Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease Phase 2
Completed NCT03326063 - Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban Phase 2